Navigation Links
New Treatment May Beat Melanoma

In trials, advanced cancers shrunk rapidly, researchers say

THURSDAY, Sept. 24 (HealthDay News) -- An experimental treatment for advanced melanoma promotes rapid shrinking of tumors, according to a new study.

The phase I extension trial includes patients with the cancer-causing mutation of the BRAF gene, which is associated with about 50 percent of melanomas and 5 percent of colorectal cancers.

The patients were given 960 milligrams of PLX4032 twice a day. Of the 22 patients evaluated to date, 14 (64 percent) showed at least 30 percent shrinkage in the diameter of tumors for at least a month -- the official criteria for partial response to the treatment. Another six of the 22 patients also showed a response, but it was too early to determine whether the tumors would shrink enough to meet the criteria for partial response.

The findings were scheduled to be presented Thursday in Berlin at a meeting of the European Cancer Organization and the European Society for Medical Oncology.

"We are very excited about these results. Of the 22 patients we have been able to evaluate so far, 20 have had some objective tumor shrinkage. This is impressive as they all had metastatic disease, and most of them had failed several prior therapies," trial co-leader Dr. Paul Chapman, an attending physician on the melanoma/sarcoma service at Memorial Sloan-Kettering Cancer Center in New York City, said at a news briefing.

"A lot of these patients were pretty sick, but many of them had a significant and rapid improvement in the way they function. We've had patients come off oxygen, and we've got several patients who have been able to come off narcotic pain medication soon after starting treatment," Chapman said.

"What makes this treatment different from standard chemotherapy is that standard chemotherapy attacks the machinery involved in cell division; so to stop the cancer cells dividing uncontrollably, most standard chemotherapy aims to block the mechanism of division by interfering directly with DNA replication or with microtubules in the dividing cells," he explained.

"PLX4032 is different because it attacks the genetic program that is causing the cells to divide uncontrollably, and we think the BRAF mutation is driving that program. The drug is blocking the genetics of the tumor, rather than trying to interfere with the proliferation of the cells and, as a result, there are fewer side effects, although there are some. We are seeing some pretty dramatic and rapid responses, and they are occurring in sites where we rarely see responses to chemotherapy, such as in the bone."

Chapman noted that "we don't know yet how long these responses will last, and we have had patients whose cancer has progressed after initially responding; so we are putting a lot of effort into studying the patients who do relapse, trying to understand how their tumors have become resistant.

"In addition, one of the main side effects we've seen is that some patients develop early, non-melanoma skin cancers, such as squamous cell skin cancer. We are very vigilant about this, and although they are very easy to cut out, it's something we are keeping a close eye on."

A phase II trial involving 90 patients will start at the end of this year, and a phase III trial involving several hundred patients is scheduled to begin at the end of this year or early next year.

In related news from the cancer meeting in Berlin, researchers said they've shown that ultrasound can be used to identify whether cancer has started to spread in melanoma patients, and to what extent. This information can help doctors decide how much surgery, if any, a patient requires and predict the patient's likelihood of survival.

"We have identified two ultrasound patterns of lymph node metastasis in melanoma patients which can identify correctly any amount of tumor cells in the sentinel lymph nodes in 75 to 90 percent of cases before proceeding to surgery on the sentinel lymph nodes," Dr. Christiane Voit, head of the diagnostic unit at the Skin Cancer Center at the Medical University of Berlin, said in a news release prepared before the meeting.

Since 2001, she and her colleagues have tested the use of ultrasound in diagnosis and treatment planning of 850 melanoma patients. The research findings need to be confirmed in multi-center, randomized trials, Voit said.

More information

The U.S. National Cancer Institute has more about melanoma.

-- Robert Preidt

SOURCE: European Cancer Organization, European Society for Medical Oncology, news release, Sept. 23, 2009

Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Lifestyle interventions in the prevention and treatment of cancer
2. M. D. Anderson examines use of toad venom in cancer treatment
3. Michael J. Fox Foundation Commits Up to $5 Million to Help Advance Neurotrophic Factors From Promise to Reality As Parkinsons Treatment
4. Shady Grove Fertility Center Presents 5K Fundraising Race to Help Families Afford Fertility Treatment or Adoption
5. Study reveals 2/3 of prostate cancer patients do not need treatment
6. Discovery could improve hepatitis C treatment
7. Targeted heat therapy offers new standard treatment option for soft tissue sarcoma
8. National Autism Center Releases Groundbreaking Report on Autism Treatments
9. Women's Pelvic Organ Prolapse and Incontinence Guide Informs, Outlines Treatments
10. FDA Advisory Committee Unanimously Recommends Approval of XIAFLEX(TM) for Treatment of Dupuytrens Disease
11. Study of adjuvant endocrine treatment for breast cancer reveals cost of noncompliance
Post Your Comments:
Related Image:
New Treatment May Beat Melanoma
(Date:11/30/2015)... ... November 30, 2015 , ... ... Centers’ National Poison Data System (NPDS) reveals that in 2014, someone called a ... cases, over two million of which were human exposure cases. , The American ...
(Date:11/30/2015)... ... November 30, 2015 , ... Brenntag Specialties, Inc. ... partner for the Nutraceutical Specialties products into oral solid dosage in the over ... , “We are pleased to announce our expanded distribution agreement with ASI.” said ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... announced at the Radiology Society of North America (RSNA) annual meeting, being held ... 60% growth from 2014. Throughout 2015, the company has completed installations for ...
(Date:11/30/2015)... ... November 30, 2015 , ... Holcomb – Kreithen Plastic ... surgery practices in Florida, is proud to announce that Dr. Joshua Kreithen, one ... Ethicon Inc., a Johnson & Johnson Company. , Ethicon is a global medical ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... strategic alliance around Novus’ TIGR® Matrix Surgical Mesh technology for soft tissue repair ... polymers, TIGR® Matrix is a long-term resorbable surgical mesh intended to support and ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... , Nov. 30, 2015   Royal Philips ... Implant, the industry,s first MRI guided user interface and ... of patients with MR Conditional implants, such as knee ... 2015 Radiological Society of North America Annual Meeting ... and supports diagnostic confidence of this growing patient population. ...
(Date:11/30/2015)... BOCA RATON, Fla. , Nov. 30, ... of Public Research (the Institute) announced today that ... , a medical device start-up company with technology developed ... creation based on publicly-funded research, and bridges early funding ... -based universities and research institutions. ...
(Date:11/30/2015)... Nov. 30, 2015 Baxalta Incorporated ... leader dedicated to delivering transformative therapies to ... conditions, today announced the launch and first ... an extended circulating half-life recombinant factor VIII ... full-length ADVATE [Antihemophilic Factor (Recombinant)]. The treatment ...
Breaking Medicine Technology: